PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August
July 19 2021 - 5:00PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products, with its
lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to
together as “VAZALORE”), today announced that three stock-keeping
units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug
Administration (“FDA”) approved liquid-filled aspirin capsules,
will be available in over 8,000 Walgreens stores nationwide later
in August. Walgreens is a global leader in retail pharmacy.
Walgreens has already inserted placeholders to reserve space on
shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81
mg, 30 count; and VAZALORE 325 mg, 30 count.
“As we continue to execute on our commercial launch plans, we
are delighted that Walgreens has committed to carrying all three
SKUs of VAZALORE in over 8,000 of its stores throughout the
country. Walgreens’ focus on health and wellbeing aligns closely
with our mission to bring VAZALORE to the millions of people who
can benefit from our unique aspirin therapy,” stated Natasha
Giordano, Chief Executive Officer of PLx.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that
provides patients with vascular disease and diabetic patients who
are candidates for aspirin therapy based on physician
recommendation, with fast, reliable and predictable platelet
inhibition as compared to enteric-coated aspirin. It also reduces
the risk of stomach erosions and ulcers, as compared to
immediate-release aspirin, common in an acute setting. To learn
more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on
its clinically-validated and patent-protected PLxGuard™ drug
delivery platform to provide more effective and safer products. The
PLxGuard drug delivery platform works by targeting the release of
active pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0a91fca5-c90b-4bb9-b5e1-f4189df5f818
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024